Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma

10 Nov 2022

Abstract excerpt

Dedifferentiated liposarcoma (DDLPS) is an aggressive adipogenic cancer with poor prognosis. DDLPS tumors are only modestly sensitive to chemotherapy and radiation, and there is a need for more effective therapies. Genetically, DDLPS is characterized by a low tumor mutational burden and frequent chromosomal structural abnormalities including amplification of the 12q13-15 chromosomal region and the MDM2 gene,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Sarcoma Diagnosis and Treatment
Share to Cancer-related Molecular Pathways
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36439412
DOI: 10.3389/fonc.2022.1006959

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the MDM2-p53 pathway in dedifferentiated liposarcomaPMID 36439412Read ↗

MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of actionSemantic proximity Read ↗

SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated LiposarcomaSemantic proximity Read ↗

MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical TrialsSemantic proximity Read ↗

Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression driversSemantic proximity Read ↗

Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated LiposarcomaSemantic proximity Read ↗

Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response PathwaySemantic proximity Read ↗

MDM2 inhibitors in sarcomas: results and next stepsSemantic proximity Read ↗

The novel role of MDM2 in the diagnosis and treatment of dedifferentiated liposarcomaSemantic proximity Read ↗

Clinical Overview of MDM2/X-Targeted TherapiesSemantic proximity Read ↗

Clinical and Molecular Spectrum of LiposarcomaSemantic proximity Read ↗

Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.Semantic proximity Read ↗

Dedifferentiated LiposarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.